A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs UV 1 (Primary) ; Sargramostim
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ultimovacs AS
- 04 Nov 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Feb 2020.
- 05 Apr 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2020 as reported by ClinicalTrials.gov record.
- 05 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov record.